Maria Rosaria Abbattista

Committed research scientist with 13 years of experience using cutting-edge technology to generate and share important information with the academic community. Conducted new anticancer drug development research with integrity and great attention to detail.

Team player with strong organizational skills. Ability to handle multiple projects simultaneously with a high degree of accuracy.

· Served on the Faculty of Medical Sciences Masters Advisory Board from 2016 to 2019

· Acted as the Departmental Graduate Advisor (DGA) for ACSRC Masters students from 2017 to 2019

· Assumed the position of Deputy DGA for ACSRC Doctoral students between 2017 and 2019

 New Zealand Citizen / Australian Permanent Resident

Patterson, A.V., Smaill, J.B., Ashoorzadeh, A., Guise, C.P., Squire, C.J., Gamage, S.A., Abbattista, M.A., Bull, M.R., Grey, A.C., Li, X., Ding, K., Ren, X., Jiang, S., Tu, Z.' FGFR kinase inhibitors and pharmaceutical uses.' World Intellectual Property Organisation Patent WO/2018/160076.2018 

Brimble, M.A., Abbattista, M.R., Patterson, A.V., Harris, P.W.R., Smaill, J.B.M., Kavianinia, I., Stubbing, L.A. Peptide Compounds, Conjugates Thereof, and Uses Thereof. New Zealand Provisional Patent Application 748041. 2018 

Patterson, A.V., Guise, C.P., Abbattista, M.R., Wilson, W.R., Smaill, J.B., Sydall, S., Denny, W.A., Ashoorzadeh, A.' AKR1C3 as a biomarker, methods of selecting and treating patients based upon an AKR1C3 profile and compounds for use therein.' PCT International Application WO 2010044686 A1, 80pp, 2010

Abbattista, M.R., Ashoorzadeh, A., Guise, C.P., Mowday, A.M., Mittra, R., Silva, S., Hicks, K.O., Bull, M.R., Jackson-Patel, V., Lin, X., Prosser, G.A., Lambie, N.K., Dachs, G.U., Ackerley, D.F., Smaill, J.B., and Patterson, A.V. (2021). Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3. Pharmaceuticals, doi:10.3390/ph14121231.

Van der Wiel A.M.A., Jackson-Patel V., Niemans R., Yaromina A., Liu E., Marcus D., Mowday A.M., Lieuwes N.G., Biemans R., Lin X., Fu Z., Kumara S., Jochems A., Ashoorzadeh A., Anderson R.F., O Hicks K., Bull M.R., Abbattista M.R., Guise C.P., Deschoemaeker S., Thiolloy S., Heyerick A., Balbo S., Solivio M., Smaill J.B., Theys J., Dubois L.J., Patterson A.V., and Lambin P. (2021). Selectively targeting tumour hypoxia with the hypoxia-activated prodrug CP-506. Molecular Cancer Therapeutics, doi:10.1158/1535-7163.MCT-21-0406.

Guise C.P, Abbattista M.R., Anderson R.F., Li D., Taghipouran R., Tsai A., Lee S.J., Smaill J.B., Denny W.A., Hay M.P., Wilson W.R.., Hicks K.O., Patterson A.V. (2020). Subcellular location of tirapazamine reduction dramatically affects aerobic but not anoxic cytotoxicity. Molecules, 25, 4888; doi:10.3390/molecules25214888.

Li F.F., Stubbing L.A., Kavianinia I., Abbattista M.R., Harris P.W.R., Smaill J.B., Patterson A.V. and Brimble M.A. (2020). Synthesis and antiproiferative activity of C- and N-terminal analogues of culicinin D. Bioorganic and Medicinal Chemistry Letters, Ref. No.:  BMCL-D-20-00460R1.

Kavianinia,   I., Stubbing, L.A., Abbattista, M.R., Harris, P.W.R., Smaill, J.B.,   Patterson, A.V., Brinmble, M.A. (2020). Alanine scan-guided synthesis and   biological evaluation of analogues of culicinin D, a potent anticancer   peptaibol. Bioorganic and Medicinal Chemistry Letters, March 23:   127135. 

Stabbing,   L.A., Kavianinia, I., Abbattista, M.r., Harris, P.W.R., Smaill, J.B.,   Patterson, A.V., Brimble, M.A. (2019). Synthesis and antiproliferative   activity of culicinin D analogues containing simplied AHMOD-based residues. European   Journal of Medicinal Chemistry, 177, 235-246. 

Mowday, A. M., Ashoorzadeh, A., Williams,   E. M., Copp, J. N., Silva, S., Bull, M. R., . . . Patterson, A. V. (2016).   Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug   therapy. Biochemical Pharmacology, 116, 176-187.  

Abbattista, M. R., Jamieson, S. M., Gu, Y.,   Nickel, J. E., Pullen, S. M., Patterson, A. V., . . . Guise, C. P. (2015).   Pre-clinical activity of PR-104 as monotherapy and in combination with   sorafenib in hepatocellular carcinoma.Cancer   biology & therapy, 16(4),   610-622.

Foehrenbacher, A., Patel, K., Abbattista,   M. R., Guise, C. P., Secomb, T. W., Wilson, W. R., & Hicks, K. O. (2013).   The Role of Bystander Effects in the Antitumor Activity of the   Hypoxia-Activated Prodrug PR-104.Frontiers   in oncology, 3, 263.

Guise, C. P., Abbattista, M. R., Tipparaju,   S. R., Lambie, N. K., Su, J., Li, D., . . . Patterson, A. V. (2012). Diflavin   Oxidoreductases Activate the Bioreductive Prodrug PR104A Under Hypoxia. Mol Pharmacol, 81(1), 31-40.  

Gu, Y., Guise, C. P., Patel, K.,   Abbattista, M. R., Li, J., Sun, X., . . . Wilson, W. R. (2011). Erratum to:   Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug   PR-104 in mice. Cancer Chemotherapy and   Pharmacology, 67(5), 1209.  

Gu, Y., Guise, C. P., Patel, K.,   Abbattista, M. R., Lie, J., Sun, X., . . . Wilson, W. R. (2011). Reductive   metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.Cancer Chemotherapy and Pharmacology, 67(3), 543-555.

Guise, C. P., Abbattista, M. R., Singleton,   R. S., Holford, S. D., Connolly, J., Dachs, G. U., . . . Patterson, A. V.   (2010). The Bioreductive Prodrug PR-104A Is Activated under Aerobic   Conditions by Human Aldo-Keto Reductase 1C3. CANCER RES, 70(4),   1573-1584.  

Abbattista, M. R., & Schena, F. P. (2004).   Stem cells and kidney diseases.Minerva   medica, 95(5), 411-418.

Schena, F. P., & Abbattista, M. R.   (2003). Stem cells: reparative medicine and nephrology. Journal of nephrology Vol. 16 Suppl 7 (pp. S1-S5).